A Multicenter, Randomized, Double-Blind, Double-Dummy, Active Controlled Study Comparing the Safety and Efficacy of Risankizumab to Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis
Phase of Trial: Phase III
Latest Information Update: 31 Oct 2018
At a glance
- Drugs Risankizumab (Primary) ; Methotrexate
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Sponsors AbbVie
- 28 Sep 2018 Planned End Date changed from 10 Sep 2021 to 20 Sep 2021.
- 17 Aug 2018 Status changed from not yet recruiting to recruiting.
- 06 Jun 2018 Planned End Date changed from 31 Aug 2021 to 10 Sep 2021.